Nektar Therapeutics
Nektar Therapeutics develops medicines for immunotherapy globally. Theyre developing rezpegaldesleukin for lupus erythematosus and ulcerative colitis, and atopic dermatitis and psoriasis. Rezpegaldesleukin is in phase 2 clinical trials. NKTR-255 is an IL-15 receptor agonist in phase 1 clinical trial to treat cancer. The company has collaborations with several major pharmaceutical companies. Nektar was incorporated in 1990 and is headquartered in San Francisco, California.
Overview
Strengths
- No significant strengths identified based on the analyzed metrics.
Weaknesses
- No sign of a competitive advantage: return on invested capital (latest 0.0%) has been below its cost of capital of 9.8% in each of the last 6 years.
- Operating profit does not cover interest expense.
- Our discounted cash flow model finds no value to support the current price: operating profit does not cover interest expense.
- Shareholder dilution: the share count has grown by 17.5% a year over the last three years.
- Currently loss-making: the latest fiscal year closed with a net loss.
- Unreliable cash generation: free cash flow was negative in 6 of the last 6 years.
Key Financial Data